Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

GERN

Geron Corp

Dec 12 • 04:00PM ET

3.92

Dollar change -0.06
Percentage change -1.51	%

Healthcare • Biotechnology • USA • NASD

Peers: GILD FATE EXEL ACAD BGNE PTCT ALLO ETON IMMP ATNM

| Held by: VTI IWM XBI VXF IBB IWO VTWO SCHA PJP IWN

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.32	Insider Own	6.59%	Shs Outstand	603.10M	Perf Week	-1.51%
Market Cap	2.37B	Forward P/E	-	EPS next Y	-0.08	Insider Trans	-1.66%	Shs Float	564.66M	Perf Month	-1.26%
Income	-201.19M	PEG	-	EPS next Q	-0.03	Inst Own	78.41%	Short Float	11.75%	Perf Quarter	-13.08%
Sales	29.48M	P/S	80.38	EPS this Y	18.80%	Inst Trans	11.11%	Short Ratio	8.15	Perf Half Y	-19.67%
Book/sh	0.48	P/B	8.09	EPS next Y	71.04%	ROA	-46.90%	Short Interest	66.35M	Perf Year	103.11%
Cash/sh	0.57	P/C	6.94	EPS next 5Y	5.00%	ROE	-69.03%	52W Range	1.64 - 5.34	Perf YTD	85.78%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-16.08%	ROI	-65.53%	52W High	-26.59%	Beta	0.52
Dividend TTM	-	Quick Ratio	2.74	Sales past 5Y	46.26%	Gross Margin	94.51%	52W Low	139.02%	ATR (14)	0.16
Dividend Ex-Date	-	Current Ratio	2.89	EPS Y/Y TTM	5.76%	Oper. Margin	-705.46%	RSI (14)	43.57	Volatility	3.55% 4.19%
Employees	141	Debt/Eq	0.30	Sales Y/Y TTM	9199.68%	Profit Margin	-682.48%	Recom	1.11	Target Price	7.61
Option/Short	Yes / Yes	LT Debt/Eq	0.05	EPS Q/Q	48.38%	Payout	-	Rel Volume	1.32	Prev Close	3.98
Sales Surprise	49.00%	EPS Surprise	52.32%	Sales Q/Q	17138.41%	Earnings	Nov 07 BMO	Avg Volume	8.14M	Price	3.92
SMA20	-1.06%	SMA50	-3.92%	SMA200	-2.62%	Trades		Volume	10,761,250	Change	-1.51%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-05-24	Initiated	H.C. Wainwright	Buy	$8
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Sep-09-24	Initiated	Leerink Partners	Outperform	$7
Apr-30-24	Downgrade	Robert W. Baird	Outperform → Neutral	$4.50
Apr-29-24	Initiated	TD Cowen	Buy	$10
Mar-15-24	Reiterated	Needham	Buy	$4 → $5
Sep-12-23	Upgrade	Goldman	Neutral → Buy	$4
Mar-28-23	Initiated	Goldman	Neutral	$3
Oct-28-22	Initiated	Wedbush	Outperform	$5
Jul-28-22	Resumed	B. Riley Securities	Buy	$4
Nov-02-21	Initiated	Robert W. Baird	Outperform	$4
Feb-18-21	Resumed	B. Riley Securities	Buy	$4
Aug-03-20	Initiated	Stifel	Buy	$3
Nov-19-19	Resumed	B. Riley FBR	Buy	$4
Sep-03-19	Initiated	H.C. Wainwright	Buy	$4
Aug-15-19	Initiated	Cantor Fitzgerald	Overweight	$4
Apr-09-19	Upgrade	Needham	Hold → Buy	$3
Jan-31-19	Upgrade	B. Riley FBR	Neutral → Buy	$1.50 → $3.25
Oct-02-18	Downgrade	B. Riley FBR	Buy → Neutral	$5.75 → $1.50
Jul-05-18	Initiated	B. Riley FBR, Inc.	Buy	$5.75

Show Previous Ratings

Dec-10-24 09:00AM	Geron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO (imetelstat) in Combination with Ruxolitinib as Frontline Therapy in Patients with Myelofibrosis (Business Wire)
09:00AM	Geron Announces New IMerge Analyses Presented at ASH Suggesting Clinical Activity of RYTELO (imetelstat) in Patients with Lower-Risk MDS Regardless of Type or Number of Prior Therapies (Business Wire)
Nov-27-24 09:00AM	Geron to Participate in the 7th Annual Evercore ISI HealthCONx Conference (Business Wire)
Nov-21-24 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-11-24 04:30PM	Geron Corporation Announces Appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development (Business Wire)
09:00AM	Loading…
09:00AM	Geron to Participate in the Stifel 2024 Healthcare Conference (Business Wire)
Nov-08-24 07:29AM	Geron Secures $250M Funding and Strong Q3 Sales (TipRanks)
Nov-07-24 07:10AM	Royalty Pharma to Acquire Royalty Interest in Geron's RYTELO for $125 Million (GlobeNewswire)
07:01AM	Geron Corporation Announces Up to $375 Million in Funding with Royalty Pharma and Pharmakon Advisors (Business Wire)
07:00AM	Geron Corporation Reports Third Quarter 2024 Financial Results and Recent Business Highlights (Business Wire)
Nov-05-24 09:00AM	Geron Announces New Data to be Presented at Upcoming ASH Annual Meeting Highlighting the Potential of RYTELO (imetelstat) in Myeloid Hematologic Malignancies (Business Wire)
Oct-17-24 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-15-24 04:30PM	Geron to Announce Third Quarter 2024 Financial Results on November 7, 2024 (Business Wire)
Oct-12-24 12:26PM	Is Geron Corporation (GERN) the Best Growth Stock Under $10 to Buy? (Insider Monkey)
Oct-10-24 09:36AM	Is Geron Corporation (GERN) the Best Stock Under $10 With High Potential? (Insider Monkey)
05:27PM	Loading…
Oct-09-24 05:27PM	Geron Corp (GERN) Q2 2024 Earnings Call Highlights: Strong Financial Position Amid Early Rytelo ... (GuruFocus.com)
08:04AM	Wall Street Analysts Rate Geron Corporation (GERN) as a Buy Amid Strong Growth Prospects (Insider Monkey)
Sep-19-24 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-09-24 04:15PM	Geron Corporation Announces Appointment of Jim Ziegler as Chief Commercial Officer (Business Wire)
Aug-22-24 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-08-24 07:00AM	Geron Corporation Reports Second Quarter 2024 Financial Results and Business Highlights (Business Wire)
Jul-26-24 07:30AM	Geron Announces Updated NCCN Guidelines Recommending RYTELO (imetelstat) for the Treatment of Symptomatic Anemia in Patients with Lower-Risk MDS (Business Wire) +8.62%
Jul-23-24 04:15PM	Geron Corporation Announces Chief Commercial Officer to Depart at End of August 2024 (Business Wire) -7.14%
Jul-18-24 04:30PM	Geron to Announce Second Quarter 2024 Financial Results on August 8, 2024 (Business Wire)
Jul-11-24 02:23PM	3 Under-$10 Biotech Stocks That Could Make You Rich (InvestorPlace)
Jul-08-24 07:09PM	3 Longevity Stocks to Buy for Anti-Aging Breakthroughs (InvestorPlace)
Jun-20-24 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-11-24 10:00AM	3 Penny Stocks to Buy if You Want to Spend Less and Earn More (InvestorPlace)
Jun-10-24 11:58AM	Geron (GERN) Wins FDA Approval for Blood Cancer Drug, Stock Up (Zacks) +9.80%
Jun-07-24 03:51PM	Geron stock pops on FDA approval for blood cancer drug (Yahoo Finance Video) +17.99%
03:24PM	Loading…
03:24PM	Geron Stock Soars on FDA Approval of Drug for Patients With Rare Blood Cancers (Investopedia)
01:10PM	Stocks shrug off hot jobs report, GameStop sinks, Nvidia stock split on tap: Yahoo Finance (Yahoo Finance Video)
11:21AM	FDA Reverses Juul Ban. What Comes Next? (InvestorPlace)
11:02AM	Why Is Geron (GERN) Stock Up 18% Today? (InvestorPlace)
07:22AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
Jun-06-24 09:58PM	Geron Announces FDA Approval of RYTELO (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent Anemia (Business Wire)
May-16-24 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-03-24 10:34AM	Geron Corporation (NASDAQ:GERN) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-02-24 12:55PM	GERN Stock Earnings: Geron Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:20AM	Geron (GERN) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Geron Corporation Reports First Quarter 2024 Financial Results and Business Highlights (Business Wire)
06:46AM	The Top 3 Penny Stocks to Buy in April 2024 (InvestorPlace)
Apr-25-24 04:30PM	Geron to Announce First Quarter 2024 Financial Results on May 2, 2024 (Business Wire) +6.46%
Apr-18-24 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-03-24 04:30PM	Geron to Participate at Upcoming Investor Conferences in April (Business Wire)
Mar-19-24 09:07AM	Geron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants (Business Wire)
Mar-15-24 03:50PM	Geron, Madrigal Pharmaceuticals jump on good news from FDA (Yahoo Finance Video) +92.00%
01:29PM	Stocks to Watch Friday: Adobe, Ulta, Fisker (The Wall Street Journal)
10:47AM	Why Is Geron (GERN) Stock Up 94% Today? (InvestorPlace)
08:57AM	Geron (GERN) Gets ODAC Votes for Blood Disorder Drug, Shares Up (Zacks)
05:00AM	Geron triumphs in FDA AdComm battle, securing 12-2 vote in favor of blood cancer drug imetelstat (FierceBiotech.com)
Mar-14-24 03:54PM	Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS (Business Wire)
Mar-13-24 10:48AM	Implied Volatility Surging for Geron (GERN) Stock Options (Zacks) -6.91%
Mar-12-24 12:28PM	Geron faces uphill battle at FDA meeting, as agency questions benefit-risk profile of imetelstat (FierceBiotech.com) -12.15%
Mar-08-24 04:20PM	Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q4 2023 Earnings Call Transcript (Insider Monkey) +7.14%
Feb-28-24 07:05AM	Geron Corporation Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results (Business Wire) -5.57%
Feb-22-24 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-14-24 04:30PM	Geron to Announce Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024 (Business Wire)
Jan-18-24 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-12-24 08:30AM	Geron to Participate in the B. Riley Securities Virtual Oncology Conference (Business Wire)
Dec-21-23 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-11-23 04:15PM	Geron Announces IMerge Phase 3 Presentations at ASH Highlighting Significant Durability of Transfusion Independence and Breadth of Effect Across MDS Subgroups with Imetelstat in Lower Risk MDS (Business Wire) -6.76%
Dec-06-23 08:00AM	Geron Announces Fifty Percent Enrollment in the Phase 3 IMpactMF Clinical Trial Evaluating Imetelstat in Patients with Relapsed/Refractory Myelofibrosis (Business Wire)
Dec-04-23 05:00AM	Geron Announces Publication in The Lancet of Results from the IMerge Phase 3 Clinical Trial Evaluating Imetelstat in Lower Risk MDS (Business Wire) -6.53%
Nov-28-23 08:00AM	Geron Corporation Announces Appointment of Gaurav Aggarwal, M.D., to its Board of Directors (Business Wire)
Nov-16-23 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.35%
Nov-07-23 04:30PM	Geron to Participate at Upcoming Investor Conferences in November (Business Wire)
Nov-02-23 09:00AM	Geron IMerge Phase 3 Presentations at Upcoming ASH Annual Meeting Reinforce Significant Durability and Breadth of Effect of Imetelstat in Lower Risk MDS (Business Wire) -7.77%
08:00AM	Geron Corporation Reports Business Highlights and Third Quarter 2023 Financial Results (Business Wire)
Oct-26-23 04:30PM	Geron to Announce Third Quarter 2023 Financial Results on November 2, 2023 (Business Wire)
Oct-19-23 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-12-23 03:26PM	Buy These 2 Beaten-Down Stocks, Goldman Sachs Says, Forecasting up to 130% Upside (TipRanks) -5.41%
Sep-29-23 08:00AM	Geron Announces EMA Validation of Marketing Authorization Application for Imetelstat for the Treatment of Lower Risk MDS (Business Wire)
Sep-11-23 04:30PM	Geron Announces Appointment of Michelle Robertson as Executive Vice President, Chief Financial Officer and Treasurer, and the Retirement of Olivia Bloom, Geron's Long-Time Chief Financial Officer (Business Wire)
Sep-07-23 08:00AM	Geron Announces Data Presentations from IMerge Phase 3 Evaluating Imetelstat in Lower Risk MDS at Society of Hematologic Oncology Annual Meeting (Business Wire)
Sep-05-23 04:30PM	Geron to Participate in the Baird 2023 Global Healthcare Conference (Business Wire)
Aug-22-23 08:00AM	Geron Announces PDUFA Date for Imetelstat NDA in Lower Risk MDS (Business Wire) -13.31%
Aug-21-23 08:00AM	Geron Announces FDA Acceptance of New Drug Application for Imetelstat for the Treatment of Lower Risk MDS (Business Wire)
Aug-17-23 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.56%
Aug-03-23 04:05PM	Geron Corporation Reports Business Highlights and Second Quarter 2023 Financial Results (Business Wire) -6.33%
Jul-27-23 04:30PM	Geron to Announce Second Quarter 2023 Financial Results on August 3, 2023 (Business Wire) +5.65%
Jul-20-23 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-29-23 08:30AM	Geron Announces U.S. Expanded Access Protocol for Imetelstat in Lower Risk MDS (Business Wire)
Jun-22-23 04:30PM	Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-20-23 09:00AM	Geron Announces Submission of New Drug Application to FDA for First-in-Class Telomerase Inhibitor Imetelstat (Business Wire) +5.00%
Jun-13-23 09:00AM	Geron Announces First Patient Dosed in Investigator-Led Phase 2 IMpress Trial Evaluating Imetelstat in Patients with Relapsed/Refractory AML or Higher Risk MDS (Business Wire)
Jun-12-23 08:00AM	Geron Announces New Data and Analyses from IMerge Phase 3 Presented at EHA Reporting Robust Durability of Transfusion Independence, Evidence of Disease-Modifying Activity and Favorable Fatigue PRO in Imetelstat-Treated Lower Risk MDS Patients (Business Wire) -5.83%
Jun-07-23 04:30PM	Geron to Participate in Goldman Sachs 44th Annual Global Healthcare Conference (Business Wire)
Jun-06-23 04:30PM	Geron to Host Virtual Investor Event on June 14, 2023 (Business Wire)
Jun-02-23 03:30PM	Geron Announces ASCO Presentation Reporting Durable Continuous Transfusion Independence with Imetelstat in IMerge Phase 3 Lower Risk MDS Patients (Business Wire) +6.51%
May-25-23 05:02PM	Geron Oral Presentation at Upcoming ASCO Annual Meeting to Highlight Meaningful Continuous Transfusion Independence Observed in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3 (Business Wire)
May-18-23 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-11-23 10:02AM	Geron Presentations at Upcoming EHA Annual Meeting to Report Updated Durability, Disease Modification and Favorable Patient Reported Outcomes (PRO) in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3 (Business Wire)
08:00AM	Geron Corporation Reports First Quarter 2023 Financial Results and Business Highlights (Business Wire)
May-04-23 04:30PM	Geron to Announce First Quarter 2023 Financial Results on May 11, 2023 (Business Wire)
Apr-26-23 10:05AM	Geron Announces Upcoming Oral Presentation at 2023 American Society of Clinical Oncology Annual Meeting of Imetelstat Data from IMerge Phase 3 Lower Risk MDS Trial (Business Wire)
Apr-20-23 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.37%
Apr-12-23 04:40PM	Geron to Present at Upcoming Investor Conferences in April (Business Wire)
Mar-16-23 05:45PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
04:05PM	Geron Corporation Reports Fourth Quarter and Full Year 2022 Financial Results and Upcoming Milestones (Business Wire)

Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Foster City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GRETHLEIN ANDREW J	EVP, Chief Operating Officer	Jul 08 '24	Option Exercise	1.72	674,348	1,159,879	674,348	Jul 10 04:05 PM
GRETHLEIN ANDREW J	EVP, Chief Operating Officer	Jul 08 '24	Sale	4.56	674,348	3,073,004	0	Jul 10 04:05 PM
Feller Faye	EVP, Chief Medical Officer	Jun 10 '24	Option Exercise	1.19	287,900	341,693	155,400	Jun 12 04:05 PM
Feller Faye	EVP, Chief Medical Officer	Jun 10 '24	Sale	4.63	287,900	1,334,129	0	Jun 12 04:05 PM
Kapur Anil	EVP, Corp Strategy & CCO	Jun 10 '24	Option Exercise	1.06	421,875	447,188	421,875	Jun 12 04:05 PM
Kapur Anil	EVP, Corp Strategy & CCO	Jun 10 '24	Sale	4.64	421,875	1,959,609	0	Jun 12 04:05 PM
SCARLETT JOHN A	Chairman, President and CEO	Jun 04 '24	Option Exercise	2.54	600,000	1,524,000	600,000	Jun 05 04:05 PM
SCARLETT JOHN A	Chairman, President and CEO	Jun 04 '24	Sale	4.00	600,000	2,400,000	600,000	Jun 05 04:05 PM
LAWLIS V BRYAN	Director	May 15 '24	Option Exercise	1.94	35,000	67,900	35,000	May 17 04:05 PM
LAWLIS V BRYAN	Director	May 15 '24	Sale	3.75	35,000	131,250	0	May 17 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GERN

Geron Corp

Upgrade your FINVIZ experience